Campos Guilherme R F, Almeida Nathalie Bonatti Franco, Filgueiras Priscilla Soares, Corsini Camila Amormino, Gomes Sarah Vieira Contin, de Miranda Daniel Alvim Pena, de Assis Jéssica Vieira, de Souza Silva Thaís Bárbara, Alves Pedro Augusto, da Rocha Fernandes Gabriel, de Oliveira Jaquelline Germano, Rahal Paula, Queiroz Rafaella Fortini Grenfelle, Nogueira Maurício L
Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São Paulo State, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
medRxiv. 2022 Mar 25:2022.03.24.22272904. doi: 10.1101/2022.03.24.22272904.
The emergence of the new SARS-CoV-2 Omicron variant, which is known to accumulate a huge number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. In this scenario, we evaluated the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. The percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 17% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times, indicating a positive impact of this vaccine combination in the serological immune response.
新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种的出现，与其他变种相比，已知会积累大量突变，这引发了对疫苗逃逸的担忧，尤其是对疫苗诱导产生的抗体中和作用的逃逸。在这种情况下，我们评估了在科兴疫苗（CoronaVac）初免方案后，使用一剂BNT162b2 mRNA疫苗加强针，对针对奥密克戎变种的抗体中和诱导的影响。在科兴疫苗接种方案后30天和60天血清转化的个体百分比分别为17%和10%。在接种加强针后，血清转化率提高到76.6%。在科兴疫苗接种方案中，针对奥密克戎的中和平均滴度随时间下降，但在接种加强针后，平均滴度增加了43.1倍，表明这种疫苗组合对血清学免疫反应有积极影响。
